GPCM
PASG icon

Granite Point Capital Management’s Passage Bio PASG Stock Holding History

Granite Point Capital Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,000
Closed -$530K – 168
2021
Q2 		$530K Sell
2,000
-1,750
-47% -$541K 0.02% 139
2021
Q1 		$1.31M Buy
+3,750
New +$1.6M 0.05% 121
2020
Q4 		– Sell
-5,000
Closed -$1.31M – 189
2020
Q3 		$1.31M Buy
+5,000
New +$1.72M 0.07% 110

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Granite Point Capital Management's PASG Position: Q3 2021 in Review

Granite Point Capital Management sold out of Passage Bio (PASG) in Q3 2021, closing a stake of 2,000 shares — an estimated $530K sold.

Granite Point Capital Management first reported a position in PASG in Q3 2020 and held it in 3 quarters. The position peaked at $1.31M in Q1 2021. 101 funds tracked by Wall St. Rank hold PASG as of Q3 2021.

  • Granite Point Capital Management reported no remaining Passage Bio position as of Q3 2021 after selling out during the quarter.
  • Granite Point Capital Management sold 2,000 Passage Bio shares in Q3 2021, an estimated $530K.
  • Granite Point Capital Management first reported a position in Passage Bio in Q3 2020 and held it in 3 quarters.
  • Granite Point Capital Management's Passage Bio position peaked at $1.31M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Passage Bio as of Q3 2021.

Based on Granite Point Capital Management's 13F filing for Q3 2021, filed 10 Nov 2021.